Nkwenye nke Minjuvi® (Tafasitamab) na njikọta ya na Lenalidomide maka ọgwụgwọ nke ndị okenye nwere ọrịa Lymphoma B-Cell Large Relapsed ma ọ bụ Refractory Diffuse na China

Na Mee 21, 2025, InnoCare Pharma kwupụtara na China National Medical Products Administration (NMPA) enyela ikike maka Minjuvi® (tafasitamab), ọgwụ Cd19 nke Fc gbanwere nke na-elekwasị anya na monoclonal antibody, yana lenalidomide, nke na-esote Minjuvi monotherapy, maka ọgwụgwọ nke ndị okenye nwere ọrịa lymphoma B-cell large relapted ma ọ bụ refractory diffuse (DLBCL) ndị na-erughị eru maka transplant sel autologous (ASCT). Nke a bụ ọgwụ mgbochi CD19 mbụ akwadoro maka ọgwụgwọ nke DLBCL relapted ma ọ bụ refractory na China.

Banyere Tafasitamab

Tafasitamab bụ ọgwụ mgbochi monoclonal nke e ji Fc gbanwee nke na-elekwasị anya na ọgwụ mgbochi monoclonal nke na-alụso ọrịa ọgụ. Tafasitamab nwere ngalaba Fc nke e mepụtara, nke na-eme ka mkpụrụ ndụ B dịghachi ndụ site na apoptosis na usoro mmetụta ahụ ji alụso ọrịa ọgụ gụnyere Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) na Antibody-Dependent Cellular Phagocytosis (ADCP).

MorphoSys na Incyte tinyere aka na: (a) na Jenụwarị 2020, nkwekọrịta mmekorita na ikike iji mepụta ma zụọ ahịa tafasitamab n'ụwa niile; na (b) na Febụwarị 2024, nkwekọrịta ebe Incyte nwetara ikike pụrụ iche iji mepụta ma zụọ ahịa tafasitamab n'ụwa niile.

N'ọnwa Ọgọstụ afọ 2021, Incyte tinyere aka na nkwekọrịta na ikike na InnoCare maka mmepe na azụmaahịa pụrụ iche nke tafasitamab na hematology na oncology na Greater China.

Na mba United States, Monjuvi (tafasitamab-cxix) natara nkwado ngwa ngwa site n'aka US Food and Drug Administration yana lenalidomide maka ọgwụgwọ nke ndị okenye nwere DLBCL na-alaghachi azụ ma ọ bụ na-adịghị ike nke a na-akọwapụtaghị, gụnyere DLBCL sitere na lymphoma dị ala, na ndị na-erughị eru maka transplant sel autologous (ASCT). Na Europe, Minjuvi (tafasitamab) natara ikike ahịa nke ụlọ ọrụ European Medicines Agency na njikọta ya na lenalidomide, nke sochiri ya bụ Minjuvi monotherapy, maka ọgwụgwọ nke ndị okenye nwere lymphoma B-cell large relapsed ma ọ bụ refractory diffuse (DLBCL) ndị na-erughị eru maka transplant sel autologous (ASCT).

Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.

Nọmba ekwentị: 4008803716

Email：myimmnet@163.com